IL165255A0 - A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease - Google Patents
A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's diseaseInfo
- Publication number
- IL165255A0 IL165255A0 IL16525503A IL16525503A IL165255A0 IL 165255 A0 IL165255 A0 IL 165255A0 IL 16525503 A IL16525503 A IL 16525503A IL 16525503 A IL16525503 A IL 16525503A IL 165255 A0 IL165255 A0 IL 165255A0
- Authority
- IL
- Israel
- Prior art keywords
- nmda
- antagonist
- teh
- alzheimer
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38446702P | 2002-05-31 | 2002-05-31 | |
DKPA200200844 | 2002-05-31 | ||
PCT/DK2003/000342 WO2003101458A1 (en) | 2002-05-31 | 2003-05-22 | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
IL165255A0 true IL165255A0 (en) | 2005-12-18 |
Family
ID=29713304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16525503A IL165255A0 (en) | 2002-05-31 | 2003-05-22 | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1509232B1 (xx) |
JP (1) | JP2005528431A (xx) |
AT (1) | ATE414519T1 (xx) |
AU (1) | AU2003227516B2 (xx) |
BR (1) | BR0311375A (xx) |
CY (1) | CY1108725T1 (xx) |
DE (1) | DE60324788D1 (xx) |
DK (1) | DK1509232T3 (xx) |
ES (1) | ES2314200T3 (xx) |
IL (1) | IL165255A0 (xx) |
MX (1) | MXPA04011762A (xx) |
NO (1) | NO332754B1 (xx) |
NZ (1) | NZ536603A (xx) |
PL (1) | PL373903A1 (xx) |
PT (1) | PT1509232E (xx) |
SI (1) | SI1509232T1 (xx) |
WO (1) | WO2003101458A1 (xx) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100339070C (zh) * | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
RS51540B (en) * | 2004-01-05 | 2011-06-30 | Merz Pharma Gmbh. & Co. Kgaa. | MEMANTINE FOR THE TREATMENT OF Mild to Moderate Alzheimer's Disease |
WO2005070429A1 (en) * | 2004-01-22 | 2005-08-04 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
EP1740172A4 (en) * | 2004-03-19 | 2007-10-10 | Axonyx Inc | ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER |
RU2404750C2 (ru) * | 2004-11-23 | 2010-11-27 | Адамас Фармасьютикалс, Инк. | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
CA2604052C (en) * | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of cns-related conditions |
KR101213345B1 (ko) * | 2005-04-28 | 2012-12-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항치매약을 함유하는 조성물 |
TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
NZ579310A (en) | 2007-03-01 | 2012-03-30 | Probiodrug Ag | Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
MX365650B (es) | 2009-12-02 | 2019-06-10 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
AU2011276036B2 (en) | 2010-07-05 | 2014-05-22 | Gambro Lundia Ab | An ambulatory ultrafiltration device, related methods and a computer program product |
TR201007110A2 (tr) | 2010-08-25 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Sinerjik etki gösteren kombinasyonlar |
WO2012048871A1 (en) | 2010-10-12 | 2012-04-19 | Merz Pharma Gmbh & Co. Kgaa | Memantine for improving cognitive performance in subjects |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
FR2983732B1 (fr) * | 2011-12-09 | 2013-11-22 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent |
WO2013160728A1 (en) * | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
WO2014035355A1 (en) * | 2012-08-31 | 2014-03-06 | Mahmut Bilgic | Pharmaceutical combination comprising idebenone and memantine |
WO2014055047A1 (en) * | 2012-08-31 | 2014-04-10 | Mahmut Bilgic | Combination of idebenone and donezepil |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
UA114016C2 (xx) * | 2012-12-13 | 2017-04-10 | Композиції, що містять вортіоксетин та донепезил | |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
EA038087B1 (ru) * | 2016-05-18 | 2021-07-05 | Сувен Лайф Сайенсиз Лимитед | Трехкомпонентная фармацевтическая комбинация чистых антагонистов 5-ht6 рецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора, применение указанной комбинации и содержащей ее фармацевтической композиции в лечении когнитивных расстройств и способ такого лечения |
GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
KR101938872B1 (ko) * | 2016-09-30 | 2019-01-16 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
US10548855B2 (en) * | 2016-10-28 | 2020-02-04 | Chase Pharmaceuticals Corporation | Memantine combinations and use |
TR201619184A2 (tr) | 2016-12-22 | 2018-07-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇ |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
BR112021024054A2 (pt) | 2019-05-31 | 2022-01-11 | Tecnimede Soc Tecnico Medicinal Sa | Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos. |
-
2003
- 2003-05-22 SI SI200331469T patent/SI1509232T1/sl unknown
- 2003-05-22 JP JP2004508815A patent/JP2005528431A/ja active Pending
- 2003-05-22 IL IL16525503A patent/IL165255A0/xx unknown
- 2003-05-22 ES ES03724895T patent/ES2314200T3/es not_active Expired - Lifetime
- 2003-05-22 MX MXPA04011762A patent/MXPA04011762A/es active IP Right Grant
- 2003-05-22 PT PT03724895T patent/PT1509232E/pt unknown
- 2003-05-22 NZ NZ536603A patent/NZ536603A/en not_active IP Right Cessation
- 2003-05-22 DK DK03724895T patent/DK1509232T3/da active
- 2003-05-22 WO PCT/DK2003/000342 patent/WO2003101458A1/en active Application Filing
- 2003-05-22 DE DE60324788T patent/DE60324788D1/de not_active Expired - Lifetime
- 2003-05-22 BR BR0311375-2A patent/BR0311375A/pt not_active IP Right Cessation
- 2003-05-22 PL PL03373903A patent/PL373903A1/xx not_active Application Discontinuation
- 2003-05-22 AU AU2003227516A patent/AU2003227516B2/en not_active Ceased
- 2003-05-22 EP EP03724895A patent/EP1509232B1/en not_active Revoked
- 2003-05-22 AT AT03724895T patent/ATE414519T1/de active
-
2004
- 2004-12-13 NO NO20045434A patent/NO332754B1/no not_active IP Right Cessation
-
2009
- 2009-01-21 CY CY20091100080T patent/CY1108725T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
NZ536603A (en) | 2007-06-29 |
JP2005528431A (ja) | 2005-09-22 |
DK1509232T3 (da) | 2009-02-23 |
ATE414519T1 (de) | 2008-12-15 |
DE60324788D1 (de) | 2009-01-02 |
AU2003227516A1 (en) | 2003-12-19 |
BR0311375A (pt) | 2005-03-15 |
EP1509232B1 (en) | 2008-11-19 |
AU2003227516B2 (en) | 2008-03-20 |
ES2314200T3 (es) | 2009-03-16 |
EP1509232A1 (en) | 2005-03-02 |
WO2003101458A1 (en) | 2003-12-11 |
NO332754B1 (no) | 2013-01-07 |
PT1509232E (pt) | 2009-01-07 |
PL373903A1 (en) | 2005-09-19 |
MXPA04011762A (es) | 2005-03-31 |
NO20045434L (no) | 2004-12-13 |
CY1108725T1 (el) | 2014-04-09 |
SI1509232T1 (sl) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL165255A0 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease | |
GB0223040D0 (en) | Therapeutic compounds | |
ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
MXPA04002167A (es) | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
AU6257798A (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
GB0005251D0 (en) | Therapeutic compounds | |
SI1663185T1 (sl) | Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti | |
WO1999005096A3 (en) | Urokinase inhibitors | |
HUP0302955A3 (en) | Hmg-coa reductase inhibitors, pharmaceutical compositions containing them and their use for treatment of cholesterol related diseases | |
IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
ATE234282T1 (de) | Polymorphe verbindungen | |
EP1201268A3 (en) | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | |
TR200101120T2 (tr) | Serin proteaz inhibitörü | |
AU2003231252A1 (en) | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease | |
AU3173301A (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
WO2003059254A3 (en) | Prevention and treatment of atherosclerosis and restenosis | |
GB9907571D0 (en) | Compounds | |
CA2426492A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
RS20050420A (xx) | Prevencija i lečenje alzheimer-ove bolesti | |
SE0004827D0 (sv) | Therapeutic compounds | |
EP0976404A3 (en) | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal | |
PT1276722E (pt) | Inibidores de naftamidina-uroquinase | |
RS20050514A (xx) | Jedinjenja koja inhibiraju prolil oligopeptidazu | |
WO2006020852A3 (en) | Pharmaceutical composition and method for treating neurodegenerative disorders |